Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cardiovascular disease (3) 3
cardiovascular diseases (3) 3
cerebral infarction (3) 3
diabetes (3) 3
diabetes mellitus (3) 3
health risk assessment (3) 3
hemoglobin (3) 3
medicine, general & internal (3) 3
myocardial infarction (3) 3
risk factors (3) 3
stroke (3) 3
agonists (2) 2
angina pectoris (2) 2
base-line (2) 2
blood pressure (2) 2
disease control (2) 2
drug dosages (2) 2
glucagon (2) 2
glucagon-like peptide 1 (2) 2
health risks (2) 2
heart attacks (2) 2
hypoglycemia (2) 2
incidence (2) 2
motivation (2) 2
peptides (2) 2
randomization (2) 2
risk analysis (2) 2
abridged index medicus (1) 1
abstracts (1) 1
acute coronary syndrome (1) 1
acute coronary syndromes (1) 1
aged (1) 1
angina (1) 1
angina, unstable - complications (1) 1
angina, unstable - drug therapy (1) 1
argentine literature (1) 1
borges, jorge luis (1) 1
borges, jorge luis, 1899-1986 (1) 1
borges, jorge luis, 1899-1986 translations into english (1) 1
borges, jorge luis, translations into english (1) 1
cancer (1) 1
cancer therapies (1) 1
cardiovascular diseases - mortality (1) 1
cardiovascular outcomes (1) 1
cardiovascular safety (1) 1
care and treatment (1) 1
cholesterol (1) 1
clinical trials (1) 1
committees (1) 1
control methods (1) 1
creatinine (1) 1
dance (1) 1
dentistry, oral surgery & medicine (1) 1
diabetes mellitus, type 2 - complications (1) 1
diabetes mellitus, type 2 - drug therapy (1) 1
dipeptidyl-peptidase iv inhibitors - adverse effects (1) 1
dipeptidyl-peptidase iv inhibitors - therapeutic use (1) 1
disease (1) 1
double-blind method (1) 1
drug development (1) 1
efficacy (1) 1
elderly (1) 1
enzymes (1) 1
epidermal growth factor receptors (1) 1
events (1) 1
fda approval (1) 1
female (1) 1
gastrointestinal surgery (1) 1
glycated hemoglobin a - metabolism (1) 1
history and criticism (1) 1
humans (1) 1
hypoglycemic agents - adverse effects (1) 1
hypoglycemic agents - therapeutic use (1) 1
identity (1) 1
incretin (1) 1
index medicus (1) 1
inhibitor alogliptin (1) 1
kidney diseases (1) 1
kidneys (1) 1
latin american literature (1) 1
liraglutide (1) 1
literature (1) 1
male (1) 1
mellitus (1) 1
microvasculature (1) 1
middle age (1) 1
middle aged (1) 1
myocardial infarction - complications (1) 1
myocardial infarction - drug therapy (1) 1
myocardial-infarction (1) 1
obstetrics & gynecology (1) 1
outcomes (1) 1
pancreatitis (1) 1
patient outcomes (1) 1
pediatrics (1) 1
peptidase (1) 1
peptide-1 receptor agonists (1) 1
personal development (1) 1
piperidines - adverse effects (1) 1
piperidines - therapeutic use (1) 1
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
by Gerstein, Hertzel C and Colhoun, Helen M and Dagenais, Gilles and Dagenais, Gilles R and Diaz, Rafael and Diaz, Sarahy and Lakshmanan, Mark and Pais, Prem and Probstfield, Jeffrey and Riesmeyer, Jeffrey S and Riddle, Matthew C and Rydén, Lars and Xavier, Denis and Atisso, Charles Messan and Dyal, Leanne and Hall, Stephanie and Hall, Charles and Rao-Melacini, Purnima and Wong, Gloria and Avezum, Alvaro and Basile, Jan and Chung, Ming-Min and Chung, Namsik and Chung, Jin-Wook and Conget, Ignacio and Cushman, William C and Franek, Edward and Hancu, Nicolae and Hanefeld, Christoph and Hanefeld, Markolf and Holt, Shaun and Jansky, Petr and Keltai, Matyas and Keltai, Katalin and Lanas, Fernando and Leiter, Lawrence A and Lopez-Jaramillo, Patricio and Cardona Munoz, Ernesto German and Pirags, Valdis and Pogosova, Nana and Raubenheimer, Peter J and Shaw, Jonathan E and Sheu, Wayne H-H and Temelkova-Kurktschiev, Theodora and Abella, Mercedes and Alebuena, Andrea and Almagro, Sandra and Amoroso, Eduardo and Anadon, Paula and Andreu, Elizabeth and Aristimuño, Guillermo and Arzadun, Maria and Barbieri, Maria and Barcudi, Raul and Bartolacci, Ines and Bolobanich, Gabriel and Bordonava, Anselmo and Bustamante Labarta, Miguel and Bustos, Betina and Caccavo, Alberto and Camino, Alejandra and Cantero, Maria and Carignano, Maria and Cartasegna, Luis and Cipullo, Marcela and Commendatore, Víctor and Conosciuto, Victoria and Costamagna, Osvaldo and Crespo, Claudia and Cuello, Jose and Cuneo, Carlos and Cusimano, Sandra and Dean, Sofia and Dituro, Claudio and Dominguez, Andrea and Farah, Miguel and Fernandez, Alberto and Fernandez, Florencia and Ferrari, Adriana and Flammia, Patricia and Fuentealba, Jose and Gallardo, Karina Beatriz and Garcia, Mar and Garcia, Celso and Garcia, Maria and Garcia Duran, Ruben and Garrido, Marcelo and Gavicola, Rodolfo and Gerbaudo, Claudio and Gilli, Graciela and Giotto, Ana Paula and Godoy Bolzán, Pedro and Gomez Vilamajo, Oscar and Guerlloy, Fernando and Guridi, Cristian and Gutierrez Garrido, Narcisa and Hasbani, Eduardo and Hermida, Sonia and Hominal, Miguel and Hrabar, Adrian and ... and REWIND Investigators
The Lancet, ISSN 0140-6736, 07/2019, Volume 394, Issue 10193, pp. 121 - 130
Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk... 
MEDICINE, GENERAL & INTERNAL | BASE-LINE | EVENTS | EFFICACY | SAFETY | PEPTIDE-1 RECEPTOR AGONISTS | Myocardial infarction | Heart attacks | Peptides | Control methods | Glucagon | Clinical trials | Cardiovascular disease | Population studies | Cancer therapies | Risk factors | Incidence | Randomization | Motivation | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Drug dosages | Glucagon-like peptide 1 | Women | Cerebral infarction | Enzymes | Stroke | Middle age | Diabetes mellitus | Health risks | Hypoglycemia | Risk analysis | Angina pectoris | Disease control | Cholesterol | Thyroid cancer | Agonists | Diabetes | Cardiovascular diseases | Health risk assessment | Elderly
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
by Gerstein, Hertzel C and Colhoun, Helen M and Dagenais, Gilles and Dagenais, Gilles R and Diaz, Rafael and Diaz, Sarahy and Lakshmanan, Mark and Pais, Prem and Probstfield, Jeffrey and Botros, Fady T and Riddle, Matthew C and Rydén, Lars and Xavier, Denis and Atisso, Charles Messan and Dyal, Leanne and Hall, Stephanie and Hall, Charles and Rao-Melacini, Purnima and Wong, Gloria and Avezum, Alvaro and Basile, Jan and Chung, Ming-Min and Chung, Namsik and Chung, Jin-Wook and Conget, Ignacio and Cushman, William C and Franek, Edward and Hancu, Nicolae and Hanefeld, Christoph and Hanefeld, Markolf and Holt, Shaun and Jansky, Petr and Keltai, Matyas and Keltai, Katalin and Lanas, Fernando and Leiter, Lawrence A and Lopez-Jaramillo, Patricio and Cardona Munoz, Ernesto German and Pirags, Valdis and Pogosova, Nana and Raubenheimer, Peter J and Shaw, Jonathan E and Sheu, Wayne H-H and Temelkova-Kurktschiev, Theodora and Abella, Mercedes and Alebuena, Andrea and Almagro, Sandra and Amoroso, Eduardo and Anadon, Paula and Andreu, Elizabeth and Aristimuño, Guillermo and Arzadun, Maria and Barbieri, Maria and Barcudi, Raul and Bartolacci, Ines and Bolobanich, Gabriel and Bordonava, Anselmo and Bustamante Labarta, Miguel and Bustos, Betina and Caccavo, Alberto and Camino, Alejandra and Cantero, Maria and Carignano, Maria and Cartasegna, Luis and Cipullo, Marcela and Commendatore, Víctor and Conosciuto, Victoria and Costamagna, Osvaldo and Crespo, Claudia and Cuello, Jose and Cuneo, Carlos and Cusimano, Sandra and Dean, Sofia and Dituro, Claudio and Dominguez, Andrea and Farah, Miguel and Fernandez, Alberto and Fernandez, Florencia and Ferrari, Adriana and Flammia, Patricia and Fuentealba, Jose and Gallardo, Karina Beatriz and Garcia, Mar and Garcia, Celso and Garcia, Maria and Garcia Duran, Ruben and Garrido, Marcelo and Gavicola, Rodolfo and Gerbaudo, Claudio and Gilli, Graciela and Giotto, Ana Paula and Godoy Bolzán, Pedro and Gomez Vilamajo, Oscar and Guerlloy, Fernando and Guridi, Cristian and Gutierrez Garrido, Narcisa and Hasbani, Eduardo and Hermida, Sonia and Hominal, Miguel and Hrabar, Adrian and ... and REWIND Investigators
The Lancet, ISSN 0140-6736, 07/2019, Volume 394, Issue 10193, pp. 131 - 138
Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the... 
MEDICINE, GENERAL & INTERNAL | BASE-LINE | LIRAGLUTIDE | INCRETIN | CARDIOVASCULAR OUTCOMES | DISEASE | Myocardial infarction | Therapy | Peptides | Glucagon | Cardiovascular disease | Risk factors | Incidence | Randomization | Motivation | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Urine | Creatinine | Cerebral infarction | Stroke | Kidneys | Epidermal growth factor receptors | Diabetes mellitus | Health risks | Risk analysis | Disease control | Agonists | Microvasculature | Diabetes | Kidney diseases | Renal replacement therapy | Gastrointestinal surgery | Cardiovascular diseases | Health risk assessment
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Abstracts from the 18th International Society for Research in Human Milk and Lactation Conference
by Coutsoudis, Anna and Adair, Linda S and Kuhn, Louise and Matare, Cynthia R and Mbuya, Mduduzi N. N and Tavengwa, Naume V and Ntozini, Robert and Stoltzfus, Rebecca J and Humphrey, Jean H and Berbari, Linda Shaker and Ochoa, Theresa J and Ramani, Sasirekha and Hu, Liya and Laucirica, Daniel and Bode, Lars and Yu, Ying and Smith, David F and Cummings, Richard and Kang, Gagandeep and Prasad, B.V. Venkataram and Estes, Mary K and Hinde, Katie and Breakey, Alicia and Scelza, Brooke and Lebrilla, Carlito and Valeggia, Claudia and Quinn, EA and Jasienska, Grazyna and Kaplan, Hillard and Davis, Jasmine and Hinde, Katie and Klein, Laura D and Martin, Melanie and Gurven, Michael and Guiterrez, Sarah and Wren, Hilary M and Solomons, Noel W and Scott, Dr. Marilyn E and G. Koski, Dr. Kristine and Hajeebhoy, Nemat and Baker, Jean and Winnard, Kim and Tharaney, Manisha and Nguyen, Phuong and Roy, Sumitro and Sanghvi, Tina and Nguyen, Tuan and Abebe, Yewelsew and Kamau-Mbuthia, Elizabeth and Sellen, Daniel and McAuliffe, Corey and Broe-Vayda, Jessica and Hackett, Kristy and McGuire, Michelle and McGuire, Mark and MacLean, PhD, Paul S and Bode, Lars and Autran, Chloe A and Geddes, Donna Tracy and Cannon, Anna Maria and Kakulas, Foteini and Gridneva, Zoya and Hepworth, Anna Rachel and Hartmann, Peter Edwin and Pundir, Shikha and Thorstensen, EB and Linderborg, KM and Lagström, H and Fraser, K and Wall, CR and Cameron-Smith, David and Hadsell, Darryl and Hadsell, Louise A and Olea, Walter and Ellwood, Jessica and Rijnkels, Monique and Krebs, Nancy F and Prentice, Ann and Goldberg, Gail R and Billing, Georgia and Jarjou, Landing MA and Kiely, Mairead and Sherman, Zim and Wu, Jianhua and Cole, Darren and Prentice, Ann and Rasmussen, Kathleen and Hopkins, Ann and Neville, Margaret and Talhouk, Rabih S and Bazzoun, Dana and H.A, Adissu and Fustok, Sabreen S and Lelievre, Sophie S and Groer, Maureen and Ashmeade, Terri and Dishaw, Larry and Proschold, Kaitlyn and Gilbert, Jack and Koletzko, Berthold and ...
Breastfeeding Medicine, ISSN 1556-8253, 03/2016, Volume 11, Issue 2, pp. A-3 - A-75
Abstracts | PEDIATRICS | OBSTETRICS & GYNECOLOGY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
by White, William B and Cannon, Christopher P and Heller, Simon R and Nissen, Steven E and Bergenstal, Richard M and Bakris, George L and Perez, Alfonso T and Fleck, Penny R and Mehta, Cyrus R and Kupfer, Stuart and Wilson, Craig and Cushman, William C and Zannad, Faiez and EXAMINE Investigators
The New England Journal of Medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 14, pp. 1327 - 1335
Alogliptin, a new antihyperglycemic agent of the DPP-4 class, was shown to have no significant effect on cardiovascular risk over a median treatment period of... 
INHIBITOR ALOGLIPTIN | MEDICINE, GENERAL & INTERNAL | CARDIOVASCULAR SAFETY | MELLITUS | OUTCOMES | MYOCARDIAL-INFARCTION | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Uracil - therapeutic use | Male | Myocardial Infarction - complications | Myocardial Infarction - drug therapy | Uracil - adverse effects | Angina, Unstable - drug therapy | Piperidines - therapeutic use | Angina, Unstable - complications | Piperidines - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Uracil - analogs & derivatives | Type 2 diabetes | Care and treatment | Acute coronary syndrome | Patient outcomes | Risk factors | Myocardial infarction | Heart attacks | Cardiovascular disease | Angina | Drug development | Hemoglobin | Diabetes mellitus (non-insulin dependent) | Drug dosages | Cerebral infarction | Stroke | Peptidase | Statistical analysis | Diabetes mellitus | Pancreatitis | Committees | FDA approval | Hypoglycemia | Angina pectoris | Studies | Product development | Diabetes | Acute coronary syndromes | Cardiovascular diseases | Health risk assessment | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights